Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Biliary Tract Neoplasms × surufatinib × Clear all

Phase

Phase 2 2 Phase NA 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 4 Cisplatin 4 Capecitabine 4 Oxaliplatin 3 Leucovorin 2 Fluorouracil 2 Albumin-Bound Paclitaxel 2 titanium silicide 1 tegafur-gimeracil-oteracil 1 surufatinib 1 pembrolizumab 1 mitazalimab 1 durvalumab 1 cediranib 1 anlotinib 1 Taxes 1 S 1 (combination) 1 Paclitaxel 1 Folfox protocol 1 Control Groups 1 ARRY-334543 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03873532 2020-02-13

A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

Hutchmed

Phase 2/3 Unknown

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡